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Abstract
Background: Specific cell targeting is an important, yet unsolved problem in bacteria-based therapeutic
applications, like tumor or gene therapy. Here, we describe the construction of a novel, internalin A and B (InlAB)-
deficient Listeria monocytogenes strain (Lm-spa
+), which expresses protein A of Staphylococcus aureus (SPA) and
anchors SPA in the correct orientation on the bacterial cell surface.
Results: This listerial strain efficiently binds antibodies allowing specific interaction of the bacterium with the target
recognized by the antibody. Binding of Trastuzumab (Herceptin
®) or Cetuximab (Erbitux
®) to Lm-spa
+, two
clinically approved monoclonal antibodies directed against HER2/neu and EGFR/HER1, respectively, triggers InlAB-
independent internalization into non-phagocytic cancer cell lines overexpressing the respective receptors.
Internalization, subsequent escape into the host cell cytosol and intracellular replication of these bacteria are as
efficient as of the corresponding InlAB-positive, SPA-negative parental strain. This specific antibody/receptor-
mediated internalization of Lm-spa
+ is shown in the murine 4T1 tumor cell line, the isogenic 4T1-HER2 cell line as
well as the human cancer cell lines SK-BR-3 and SK-OV-3. Importantly, this targeting approach is applicable in a
xenograft mouse tumor model after crosslinking the antibody to SPA on the listerial cell surface.
Conclusions: Binding of receptor-specific antibodies to SPA-expressing L. monocytogenes may represent a
promising approach to target L. monocytogenes to host cells expressing specific receptors triggering internalization.
Background
Bacteria-mediated tumor therapy has been investigated
for over a century [1]. The ability of bacteria to colonize
malignant tissue has been exploited in different thera-
peutic approaches [2,3].
The delivery of therapeutic agents by bacteria to the
tumor represents a promising approach to eradicate the
tumor from the inside [4,5]. A major prerequisite is the
specific bacterial colonization of tumor tissue without
simultaneous colonization of healthy tissue.
Obligate anaerobic bacteria like Clostridia or Bifido-
bacteria colonize solely the anoxic parts of tumors due
to their inability to tolerate oxygen [6,7]. For facultative
anaerobic bacteria like Salmonella, Escherichia, Vibrio
or Listeria, specific tumor colonization has been
described and different therapeutic approaches were
investigated [4,8-11]. In general, virulence-attenuated
Gram-positive bacterial pathogens, such as Listeria
monocytogenes, may be better suited for the systemic
application of bacteria in tumor therapy as these bac-
teria lack the LPS of gram-negative bacteria. LPS may
induce strong immune reactions culminating in septic
shock after release into the blood stream.
Listeria monocytogenes (Lm) has been successfully stu-
died as carrier for the delivery of DNA and RNA into
mammalian cells [12,13]. In this case pathogenicity of
the listerial carrier strain was attenuated by the deletion
of aroA [14]. In contrast to most other applied viru-
lence-attenuated Lm strains [10,15,16], the aroA mutant
possesses all virulence factors, thus enabling the carrier
bacteria to invade mammalian cells, escape from the
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any medium, provided the original work is properly cited.phagosome, and replicate in the cytosol of infected host
cells. The intracellular replication rate of the aroA
mutant was, however, lower compared to the according
wild-type strain and the capability of cell-to-cell spread
was drastically reduced [14].
The cytosolic life cycle of Lm poses an advantage for
the delivery of nucleic acids harboring eukaryotic
expression cassettes compared to other intracellular
bacteria like Salmonella, which reside and replicate in
phagosomal compartments. The utilization of Lm as a
carrier for the direct delivery of prodrug-converting-
enzymes and for the introduction of DNA encoding
these enzymes into tumor cells in vitro was successfully
assessed recently [17]. Internalization of Lm into non-
phagocytic mammalian cells is mainly triggered by the
two internalins A and B encoded by the inlAB operon
[reviewed in 18]. The deletion of inlAB thus strongly
reduces the ability of Lm to actively invade such host
cells, but does not change their passive uptake by pha-
gocytic cells.
The targeting of carrier microorganisms to cell surface
proteins of specific cells was first performed in viral
gene therapy [19]. By genetic fusion of Staphylococcus
aureus protein A (SPA) to viral coat proteins monoclo-
nal antibodies recognizing specific receptors on the tar-
g e tc e l l sw e r ef i x e dt ot h ev i r a ls u r f a c e .D u et ot h e
thereby achieved specific virus/cell interaction, uptake of
the viral carrier by the selected target cells could be
obtained. Alternatively, single chain antibody fragments
(scFv) were expressed on the viral surface which - by
the interaction with specific receptors on the host cell
surface - led to preferential viral infection of the specific
target cells as well.
Many tumor cells overexpress specific marker proteins
on their surface which include oncoproteins. HER1
(ErbB1) and HER2 (ErbB2), members of the EGFR/HER
family, represent such prominent surface proteins
[20,21]. Enhanced expression or mutational activation of
these cell surface proteins leads to tumor progression
and generally correlates with poor prognosis in tumor
therapy [reviewed in 22]. Both tumor markers, HER1
and HER2, are specifically recognized by the chimeric/
humanized monoclonal antibodies, Erbitux (Cetuximab)
and Herceptin (Trastuzumab) which are approved for
therapy of colorectal carcinoma and breast cancer,
respectively.
Antibody-mediated targeting of bacteria to tumor cells
was described so far only for Salmonella enterica sero-
var Thyphimurium expressing a scFv against carcino-
embryonic-antigen CEA. Antibody expression resulted
in a 2-fold increase of these bacteria in the tumor tissue
[23].
As a novel approach we describe in this study the
construction of a virulence-attenuated Lm strain with
deletions in inlAB and aroA which expresses functional
SPA anchored to the cell wall. This strain, when coated
with Herceptin or Erbitux, triggered a highly efficient,
InlAB-independent internalization into tumor cell lines
over-expressing HER1 and HER2, respectively, but not
into cell lines lacking these receptors. In a xenograft
murine tumor model we could also observe a significant
increase in tumor colonization of this Lm strain after
intravenous injection when the respective antibody was
covalently crosslinked to the surface-exposed SPA.
Results
Expression of recombinant SPA by internalin A and B
deficient L. monocytogenes and its correct orientation on
the listerial cell surface
AS . a ureus protein A (SPA)-expressing Lm strain was
constructed by replacing the non-essential phage inte-
grase/recombinase gene int in the genome of the listerial
mutant ΔtrpS,aroA,inlA/B × pFlo-trpS by the spa gene
(encoding the protein A). SPA is controlled by the lister-
iolysin (hly) promoter (Phly). The Phly carrying DNA
fragment contained the signal sequence of hly which was
fused in frame to the spa gene. The spa gene sequence
encodes all five Fc binding domains and the LPXTG
motif for sortase-dependent anchoring of the SPA pro-
tein to peptidoglycan [24]. The expressed SPA protein
thus contains all regions necessary for efficient transloca-
tion across the bacterial cell membrane and for anchor-
ing SPA to the cell wall of Lm.T h i sLm strain (ΔtrpS,
aroA,inlA/B,int::Phly-spa ×p F l o - trpS) is named Lm-spa
+
in the following.
Expression of SPA by the constructed Lm strains was
analyzed by Western blotting using polyclonal protein A
antibody. Bacterial cell surface and cytoplasmic protein
fractions were examined after growth of Lm-spa
+ in BHI
containing 1% amberlite XAD-4. Addition of XAD-4 to
the culture medium enhances the activity of the virulence
gene activator PrfA and hence leads to an enhanced tran-
scription of the spa gene which is under the control of
the PrfA-dependent hly promoter [25]. SPA was readily
detected in the cell surface protein fraction of Lm-spa
+
and to a lower extent in the internal protein extract frac-
tion. (Figure 1A). As expected, no SPA was present in the
parental strain ΔtrpS,aroA,inlA/B × pFlo-trpS,t e r m e d
Lm-spa
- (Figure 1A).
Fc-mediated binding of antibodies to SPA on the surface
of L. monocytogenes
The functionality of Fc-mediated binding of antibodies
to SPA on the surface of Lm-spa
+ was first tested by
immunofluorescence microscopy of Lm-spa
- and Lm-
spa
+ after incubation of the bacteria with polyclonal rab-
bit antibodies directed against ovalbumin (OVA). After
addition of FITC-conjugated OVA no fluorescence was
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-, while the Lm-spa
+ strain showed
a strong fluorescence (Figure 1B).
A more quantitative analysis of SPA expression was
performed by flow cytometry after staining Lm-spa
+ and
Lm-spa
- with FITC-conjugated rabbit-anti-goat-antibo-
dies. Lm-spa
- bacteria showed no staining while the Lm-
spa
+ bacteria were stained almost completely (Figure 1C).
In addition, the number of SPA molecules per bacterial
cell was determined indirectly. For this goal Lm-spa
+ was
incubated simultaneously with a primary antibody against
native albumin as model protein in the presence of an
excess of albumin. The bacteria bound the albumin-
loaded antibody to their surface via SPA and later on the
amount of bound protein was quantified. Therefore the
samples were denatured in Laemmli buffer and size sepa-
rated by SDS-PAGE. Subsequently the amount of bound
albumin was determined by Western blot analysis using a
primary antibody recognizing denatured albumin.
Untreated Lm-spa
+ did not bind albumin, while Lm-spa
+
coated with the albumin-specific antibody bound albu-
min (Figure 1D).
Computer aided comparison of the band intensity of
bacterially bound albumin with the known protein
amount of the positive control revealed a 7 times higher
signal intensity. Thus 70 ng albumin were bound to 5 ×
10
8 bacterial cells. With albumin having a protein mass
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Figure 1 Expression of S. aureus protein A (SPA) on the cell surface of L. monocytogenes strain ΔtrpS,aroA,inlA/B,int::Phly-spa ×p F l o -
trpS (Lm-spa
+).( a) Western blot analysis with polyclonal goat-anti-Protein A antibody of protein extracts from ΔtrpS,aroA,inlA/B × pFlo-trpS (Lm-
spa
-, lanes 1 and 2) and Lm-spa
+ (lanes 3 and 4); lanes 1 and 3: cell surface protein extracts; lanes 2 and 4: internal protein extracts. The arrow
indicates the position of SPA in the SDS-PAGE. (b) Immunofluorescence micrographs showing specific binding of antibody Fc-part to SPA on the
surface of Lm-spa
+. Lm-spa
+ were incubated with polyclonal anti-OVA antibody and stained with OVA-FITC protein (vii-ix). Lm-spa
- stained with
antibody and OVA-FITC (i-iii) and Lm-spa
+ stained without antibody but with OVA-FITC protein (iv-vi) were used as negative controls. Phase
contrast pictures are shown in the left column; FITC-stained images in middle column; picture overlays in the right column. (c) Flow cytometry
quantifying the specific Fc-mediated antibody binding to SPA on the surface of L. monocytogenes strains. Mid-logarithmic grown bacteria were
stained with polyclonal FITC-conjugated rabbit-anti-goat immunoglobulin G (H+L). Grey area indicates strain Lm-spa
-, while the white area
indicates strain Lm-spa
+.( d) Western blot analysis was used for indirect quantitation of protein A on the surface of Lm-spa
+.5×1 0
8 bacteria
were incubated simultaneously with antibody directed against native albumin and an excess of albumin. After incubation bacteria were washed
and the amount of albumin bound to the bacteria via antibody was quantified by Western blot analysis with a primary antibody directed
against denatured albumin. In the right lane 10 ng of pure serum albumin was applied as control.
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9 molecules.
Divided by the number of bacteria employed for the
coating (5*10
8 CFU) approximately 120 albumin mole-
cules were bound per bacterial cell. Assuming two
bound albumin molecules per antibody and one anti-
body per SPA molecule, this means that at least 60 SPA
molecules are exposed in the correct orientation on the
surface of each Lm-spa+ cell.
Internalization of antibody coated Lm-spa
+ into cancer
cell lines expressing the respective antibody ligand
After the successful demonstration of SPA binding to
the bacterial surface, it was important to investigate
whether the binding of tumor receptor-specific antibo-
dies to SPA on the surface of Lm-spa
+ can mediate spe-
cific cell recognition and internalization of the bacteria
into the tumor cells. The mouse mammary gland cell
line 4T1 (HER1- and HER2 negative) and the isogenic
cell line 4T1-HER2 (stably transfected with human-
HER2 [26]) were used in these experiments as well as
the monoclonal antibodies Cetuximab and Trastuzumab
directed against HER1 and HER2, respectively. Both
mAbs belong to the same IgG1 subclass of immunoglo-
bulins, but Cetuximab is a mouse/human chimeric anti-
body whereas Trastuzumab is almost completely
humanized. Cetuximab is therefore a control for unspe-
cific antibody coating of Lm-spa
+ when analyzing the
interaction of these bacteria with murine 4T1-HER2
cells.
The Lm EGDe wild-type strain was able to efficiently
enter both cell lines 4T1 and 4T1-HER2 (data not
shown). As expected, the Lm-spa
- strain (which is
InlAB-negative) was not internalized by 4T1 or 4T1-
HER2 cells regardless of whether these bacteria were
incubated with Cetuximab or Trastuzumab (Additional
file 1a, c). Lm-spa
+ was also unable to enter 4T1 and
4T1-HER2 cells without antibody coating or with Cetux-
imab coating. However, high internalization of Lm-spa
+
into 4T1-HER2 cells was observed when these bacteria
were coated with Trastuzumab (Figure 2A, Additional
file 1e).
Lm-spa
- was also not internalized by the human SK-BR-3
and SK-OV-3 cancer cells (both expressing HER1 and
HER2) in the presence or absence of the two mAbs
(Additional file1b, d). In contrast Lm-spa
+ coated with
either Cetuximab or Trastuzumab, but not the uncoated
Lm-spa
+, was able to enter these cells efficiently (Figure
2B, Additional file 1f).
As shown in Figure 2A and 2B the coating of Lm-spa
+
with the receptor-specific antibody led to a highly signif-
icant increase of Lm-spa
+ internalization (ranging from
2×1 0
2-t o1 0
4-fold) into tumor cells expressing the
respective receptor on the surface. Antibody mediated
internalization was followed by bacterial escape into the
host cell cytosol and replication as examined by immu-
nofluorescence (Additional file 2).
Herceptin-mediated internalization of Protein A coated
beads into the 4T1-HER2 cell line
Trastuzumab coated beads of 2.8 μmd i a m e t e rw e r e
used to assess whether this antibody alone is able to
induce internalization of large particles into a cell line
expressing the HER2 receptor. Alexa Fluor 488 labeled
Trastuzumab (Trastuzumab-Alexa488) was efficiently
bound by Dynabeads Protein A (Invitrogen, beads),
while the goat a-human Cy5 antibody could not be
bound directly (Figure 3, II; Additional file 3). If the
beads were preincubated with Trastuzumab or Cetuxi-
mab, a-human Cy5 antibody efficiently bound to this
antibody, indirectly labelingt h i sb e a d s( F i g u r e3 ,I I I ;
Trastuzumab
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Figure 2 Internalization of Cetuximab- or Trastuzumab- coated Lm-spa
+ relative to uncoated Lm-spa
+ (-mAb) into different cell lines.
(a) Mouse mammary cancer cell line 4T1, the HER2 transduced isogenic 4T1-HER2 and (b) the human mammary/ovary cancer cell lines SK-BR-3
and SK-OV-3, respectively, were infected with Lm-spa
+ after coating with different antibodies. Intracellular colony forming units (CFU) were
determined after gentamicin treatment by serial plating and the internalization rate of the antibody-coated relative to the uncoated bacteria was
calculated.
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with Trastuzumab-Alexa488, while red ones bound a-
human Cy5 antibody.
Beads were coated with Trastuzumab-Alexa488 and
incubated with 4T1-HER2 cells. Following this incuba-
tion Cy5 labeled a-human antibody was added into the
supernatant, resulting in a double staining of extracellu-
lar beads. Beads without antibody treatment prior to
incubation with eukaryotic cells were found to remain
completely extracellular (Additional file 4). In contrast
some of the beads treated with Trastuzumab or Trastu-
zumab-Alexa488 were located intracellular (Figure 3, III,
IV). Only pretreatment with Trastuzumab and its
labeled derivate allowed internalization of beads into
this cell line, Cetuximab did not trigger internalization
(data not shown). Thus, Trastuzumab is sufficient to
mediate internalization of beads, larger than bacteria,
into the 4T1-HER2 cell line.
Serum strongly reduces the internalization of antibody-
coated Lm-spa
+
For the evaluation of antibody-mediated targeting in vivo
Lm-spa
+ was coated with Trastuzumab and 1 × 10
8 bac-
teria were injected i.v. into Balb/c SCID mice bearing 4T1-
HER2 tumors. In a control group equal numbers of
uncoated Lm-spa
+ were used. In contrast to the in vitro
data where Lm-spa
+ coated with Trastuzumab showed
highly significant internalization into 4T1-HER2 cells
compared to uncoated Lm-spa
+ (Figure 2A), no significant
difference of the bacterial counts in liver, spleen or tumor
10μm
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Figure 3 Internalization of antibody coated Dynabeads Protein A into 4T1-HER2 cells. The beads were coated with the first antibody (1)
and incubated with 4T1-HER2 cells. Following washing, the cells were incubated with the second antibody (2) and analyzed by confocal
immunofluorescence microscopy. Beads labeled with (1) are located intracellular, while beads labeled with (1) and (2) are located extracellular.
Non coated beads showed no background fluorescence (I) and were efficiently coated with Trastuzumab-Alexa488. On bead-coating with
Trastuzumab or Trastuzumab-Alexa488 (II, III) some beads were located in the cell (marked with white arrowheads). Some beads remained
outside the cells (marked with black arrowheads). Presence of bead fluorescence was analyzed in image stacks of at least 5 μm thickness to
exclude false negatives (Additional file 4).
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coated or -uncoated Lm-spa
+ (Additional file 5). To rule
out the possibility that during the blood passage the non-
covalently bound mAbs on the surface of the coated Lm-
spa
+ bacteria might be displaced by the IgG antibodies of
the blood serum fresh murine serum was added to Trastu-
zumab-coated Lm-spa
+ bacteria prior to in vitro infection
of 4T1-HER2 cells. This treatment completely abolished
the specific internalization and the coated Lm-spa
+
behaved like uncoated Lm-spa
+ bacteria (Figure 4).
To prevent the displacement of the SPA-bound antibody
by serum antibodies we covalently linked Trastuzumab
to SPA on the bacterial surface with Dimethyl pimeline-
diimidate dihydrochloride (DMP), a homobifunctional
imidoester cross-linker. The concentration of DMP and
the incubation conditions were evaluated to achieve
optimal crosslinking and bacterial viability (data not
shown). Treatment of Lm-spa
+ with DMP under these
conditions did not alter the internalization efficiency sig-
nificantly, but largely prevented the negative effect of
murine serum on the internalization of Trastuzumab-
coated Lm-spa
+ into 4T1-HER2 cells in vitro (Figure 4).
Targeting of Lm-spa
+ coated with covalently bound
antibody to 4T1-HER2 tumors in mice
The above described in vitro data showing that the anti-
body can be covalently linked to SPA on the surface of
Lm-spa
+ without losing the bacterial viability encouraged
us to modified antibody-targeted bacteria in the mouse
tumor model system. Briefly, Balb/c SCID mice carrying
4T1-HER2 tumors were injected i.v. with 1 × 10
8 Lm-spa
+ bacteria coated with Trastuzumab crosslinked to SPA.
Similarly treated Cetuximab-coated Lm-spa
+ bacteria
were included in this in vivo experiment as a negative
control. One day after infection the bacterial counts were
determined in liver, spleen and tumor. For the distinction
of intra- and extracellularly replicating bacteria, the
tumor tissue was enzymatically digested to obtain a single
cell-suspension, part of which was treated with gentami-
cin to kill the extracellular bacteria while the other part
remained untreated to allow the determination of the
total bacterial counts in the tumor. Both fractions were
plated in serial dilutions to obtain viable bacterial counts
( C F U ) .A ss h o w ni nF i g u r e5i n j e c t i o no ft u m o rb e a r i n g
mice with Lm-spa
+ coated with covalently bound Trastu-
zumab resulted in significantly increased CFU per cell of
tumor tissue compared to Lm-spa
+ with covalently
bound Cetuximab and uncoated Lm-spa
+ (Figure 5). This
difference was observed in the gentamicin treated as well
as in the untreated fractions but the increase is more pro-
nounced in the untreated fractions. The coating with
Trastuzumab increased the amount of bacteria 8- to
10-fold, while the amount of intracellular bacteria was
elevated only 3- to 4-fold (Figure 5). In liver and spleen a
2-fold increase of bacteria was observed with the Trastu-
zumab-coated but not with the Cetuximab-coated
Lm-spa
+.
Discussion
In this study we describe a novel approach for cell target-
ing which uses an InlA- and InlB- deficient Lm mutant
expressing SPA anchored to the cell wall. Antibodies bind
to these bacteria via their Fc part thereby enabling interac-
tion of the bacteria with receptors (or other ligands)
exposed on the surface of target cells recognized by the
antibodies. In spite of a relatively low coverage of the bac-
terial surface with SPA-bound antibodies, a highly efficient
targeting of the bacteria to the antibody-recognized tumor
cell receptors (ligands) is observed. Two clinically
approved humanized and chimeric monoclonal antibodies,
Trastuzumab and Cetuximab, respectively, directed against
the cell surface receptors HER2/neu and EGFR/HER1
respectively, were applied in this study. These receptors
are overexpressed in several types of cancer, thus repre-
senting excellent specific targets for Lm coated with Tras-
tuzumab or Cetuximab [27,28]. Antibody coated Lm
strains not only showed specific binding to tumor cell
lines but also a highly efficient internalization into tumor
cell lines. This internalization was clearly independent of
the known InlA and/or InlB-mediated invasion machinery
of Lm, as these two major invasion factors [reviewed in
18] were deleted in the antibody-coated Lm strains.
Experiments showing internalization of Trastuzumab-
coated beads into HER2 expressing cells indicate that the
internalization may be completely independent of listerial
virulence factors. The bacteria may be taken up by the
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- - + + DMP treatment
- + - + Serum treatment
+
n.a.
n.a.
10-1
100
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Figure 4 Effect of serum incubation on antibody-mediated
internalization of Lm-spa
+. The bacteria were incubated with PBS
(-mAb), Cetuximab or Trastuzumab and the antibodies were
covalently bound to protein A by crosslinking with DMP.
Subsequently the bacteria were incubated with murine serum prior
to infection of 4T1-HER2 cells. Intracellular CFU was determined
after gentamicin treatment by plating serial dilutions. The relative
internalization rate in comparison to uncoated bacteria was
calculated and is shown.
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The cellular recycling rate of the EGF-family receptors has
been shown to increase upon ligand interaction and anti-
body-mediated dimerization [29]. After Trastuzumab-
mediated internalization Lm w a sa b l et oe s c a p ei n t ot h e
cytosol, replicate and spread to adjacent cells as demon-
strated by immunofluorescence. The efficiency of these
intracellular steps was comparable to that of the corre-
sponding ΔaroA attenuated wild-type strain.
Transfer of antibody-mediated targeting into xenograft
mouse tumors was initially unsuccessful. Subsequent in
vitro experiments revealed that the incubation of the
antibody coated bacteria with murine serum completely
abrogated the specific internalization, but this effect was
largely prevented by crosslinking of the antibody to SPA
on the surface of live bacteria.
Crosslinking enabled also the targeting of the anti-
body-coated bacteria to a 4T1-HER2 xenograft mouse
tumor. The number of Trastuzumab-coated bacteria in
the tumor tissue increased 8 to 10-fold when compared
to uncoated bacteria. Although less than 5% of these
bacteria were intracellular, the bacterial count was sig-
nificantly increased relative to bacteria not coated with
Trastuzumab. This 3-fold increase in the number of
intracellular bacteria was antibody specific, since bac-
teria coated with a second antibody (Cetuximab), that
-mAb Cetuximab Trastuzumab
a b
c d
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Figure 5 Antibody-mediated targeting of uncoated (-mAb), Cetuximab- or Trastuzumab- coated Lm-spa
+ after antibody crosslinking in
xenografted mouse tumor models. In seven Balb/c SCID mice per group 4T1-HER2 tumors were induced and 14 days later the mice were
infected with 1 × 10
8 CFU of differently coated Lm-spa
+. 24 h later mice were sacrificed and tumors, liver and spleen excised aseptically. Tumors
were digested with DNAse and Dispase to obtain single cell suspensions which were plated in serial dilutions without (a) and with gentamicin
treatment (b) to determine total and intracellular bacterial counts, respectively. Depicted is the bacterial count per cell in the cell suspension.
Liver (c) and spleen (d) were homogenized and plated in serial dilutions.
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significant increase compared to uncoated bacteria.
The bacterial counts in liver and spleen were 2-fold
increased with the Trastuzumab-coated Lm compared
to the uncoated bacteria, while the Cetuximab-coated
bacteria colonized liver and spleen with a similar effi-
ciency as the uncoated ones. The humanized Trastuzu-
mab contains a larger portion of non-mouse peptide
sequences than the human/mouse chimeric Cetuximab.
Thus a stronger immune reaction against Trastuzumab
might lead to an enhanced uptake of bacteria coated
with Trastuzumab by phagocytic cells in liver and
spleen.
Recently Bereta and coworkers [23] described an alter-
native approach of antibody-mediated targeting of bac-
teria whereby a single chain antibody (scFv) was
expressed by Salmonella VNP20009. In this study the
scFv directed against CEA caused only a low increase
(about 2-fold) of the targeted bacteria in a CEA overex-
pressing tumor seven days post infection. Our approach,
which crosslinks the antibody to the surface-exposed
SPA, shows not only a better uptake of the targeted bac-
teria by the tumor (already 24 h post intravenous injec-
tion), but is also more versatile, since it requires only a
specific antibody against a cell surface-exposed ligand to
specifically target the bacteria to the ligand-producing
cells. Whether these bacteria will be subsequently inter-
nalized by the target cells will presumably depend on the
cell receptor recognized by the antibody.
Conclusions
Certainly, further studies are needed to test this promis-
ing cell targeting technology for possible therapeutic
applications (e.g. drug delivery to selected cells) but the
experiments shown here successfully demonstrate the
proof of principle of the approach.
Methods
Ethics Statement
All animals experiments were carried out in accordance
with protocols approved by the Regierung von Unter-
franken, Germany.
Bacterial strains, plasmids, media and growth conditions
All strains and plasmids used are listed in Table 1. E.coli
DH10b was used for all plasmid DNA manipulations.
Competent Lm cells were prepared and transformed by
electroporation as described by Park and Stewart [30]. All
experiments were performed with Lm grown to mid-loga-
rithmic growth phase (OD600 =0 . 8 )a t3 7 ° Cc u l t i v a t e di n
brain heart infusion (BHI, BD Difco, USA). In experiments
indicated, addition of amberlite XAD-4 to the BHI media
led to the upregulation of SPA expression in mid-logarith-
mic phase by activating PrfA and thus listeriolysin
promoter Phly. Bacteria were washed twice in 0.9% NaCl
(Applichem, Germany) solution, resuspended in 20% v/v
glycerol (Applichem, Germany) in 0.9% NaCl solution and
stored as aliquots at -80°C. Bacterial CFUs were deter-
mined by plating serial dilutions on BHI agar plates sup-
plemented with 5 μg/ml tetracycline (Sigma, Germany).
Plasmid and strain construction
To amplify the spa gene from S. aureus strain 8325 wt,
genomic DNA was used in a PCR reaction using the speci-
fic primers proteinA forward (5’-GCAAATGCATCG-
CAACACGATG-3’) and proteinA reverse (5’-TTTTCCC
GGGCGTTGTGTATTGTTT-3’). The DNA fragment
was cut with SmaI and cloned into the vector pUC18,
leading to the plasmid pUC18-spa. The fragment was then
cut and cloned into the plasmid pUC18-Phly using the
NsiI and XmaI restriction sites. The fragment Phly-spa
was PCR amplified by the Primers M13 universe 2 (5’-GT
AAAACGACGGCCATGGC-3’)a n dM 1 3r e v( 5 ’-CAGG
AAACAGCTATGAC-3’) to introduce a NcoI restriction
site. The fragment was then cloned into plasmid
pLSV101-intAB [31] using the restriction sites NcoI and
SacI. The resulting plasmid pLSV101-intAB::Phly-spa was
transformed into L. monocytogenes ΔtrpS,inlA/B × pFlo-
trpS [32] and L. monocytogenes ΔtrpS,aroA,inlA/B × pFlo-
trpS [aroA attenuated as described in 33] and a homolo-
gous recombination technique was used to construct a
deletion mutant [34]. Because trpS bearing plasmids are
f u l l ys t a b l ei nt h eΔtrpS mutant without the addition of
antibiotics this strain was used for mutant generation.
Western blot analysis
L. monocytogenes protein extracts were prepared as
described [35]. Surface proteins were extracted by incu-
bation in 1% sodium dodecyl sulfate (SDS) for 20 min.
Blotted proteins were probed with a polyclonal goat
antibody against Protein A (Biomeda, CA, USA) or poly-
clonal rabbit antibody against murine serum albumin
(ab19196 - abcam, UK). Secondary Peroxidase-conju-
gated antibodies and ECL Western blot detection
reagent (Amersham Biosciences, Germany) were used
for visualization of bands.
Analysis of bacterial protein A surface expression
Bacteria were washed in PBS and incubated for 1 h at
25°C with polyclonal FITC-conjugated rabbit-anti-goat
immunoglobulin G (H+L, Sigma, Germany) for flow
cytometry or polyclonal rabbit antibody directed against
ovalbumin (C6534, Sigma, Germany) for immunofluor-
escence microscopy. Controls were incubated with PBS.
Bacteria were washed 2-3 times with PBS and analyzed
using an Epics XL flow cytometer (Beckman Coulter) or
further incubated with FITC-conjugated OVA (Molecu-
lar Probes, Germany). After repeated washing, bacteria
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escence microscopy (Leica, Germany).
Antibody-coating, crosslinking and serum treatment of
L. monocytogenes
For antibody-coating, 5 × 10
8 CFU were washed with
PBS (pH 8.2) and resuspended in 100 μl PBS containing
2.5 μg of Cetuximab (Merck, Germany) or 2.37 μgo f
Trastuzumab (Roche, Germany), respectively. Alexa
Fluor labeled antibodies were generated using the Apex
Antibody labeling kit (Invitrogen) following the manufac-
turers guidelines. The bacteria were incubated under vig-
orous shaking for 45 min at room temperature (RT).
Bacteria were washed with PBS (pH 8.2) and diluted for
further use.
Crosslinking of antibodies to SPA on the surface of
Lm-spa
+ was performed using dimethyl pimelinediimi-
date dihydrochloride (DMP, Biochemika Fluka, Ger-
many). Freshly prepared DMP in PBS (pH 8.2) was
added at a final concentration of 0.65 mg/ml to the anti-
body coating reaction. After 45 min the bacteria were
washed with PBS (pH 8.2) and the crosslinking proce-
dure was repeated for additional 45 min with the same
concentration of DMP. Control bacteria were treated
likewise without antibody addition.
Serum treatment of bacteria was performed after coat-
ing and crosslinking prior to infection. Bacteria were
m i x e dw i t hf r e s hs e r u mf r o mn a ï v em i c ea n di n c u b a t e d
for 1 h under vigorous shaking at RT, washed with PBS
(pH 8.2) and finally diluted.
The amount of SPA per bacterial cell was determined
by Western blot analysis. 5 × 10
8 CFU were resuspended
in 100 μl PBS and 0.1 μg of anti mouse albumin antibody
(Abcam ab34807, UK) and 200 ng of serum albumin
(Sigma, Germany) were added. The suspension was
incubated under vigorous shaking for 45 min at RT. Bac-
teria were washed three times with 0.05% Tween 20 in
PBS and analyzed by SDS-PAGE and Western blotting.
Handling of Dynabeads Protein A
Dynabeads Protein A (Invitrogen, Germany) were coated
with Trastuzumab following the manufacturer’s protocol.
1.2 × 10
5 4T1-HER2 cells were seeded on cover slips in
24-well plates and incubated with antibody-labeled and
non-labeled beads. 25 μg beads were added per well in
culture medium lacking FCS. Cells were incubated 1 h at
37°C and with 5% CO2. The coverslips were washed in
PBS and fixed in 4% PFA for 10 minutes at room tem-
perature. After washing using PBS, the cells were incu-
bated with the second antibody (a-human Cy5, Abcam
ab6561, UK) for 1 h at room temperature in the dark.
Following an additional washing step in PBS the cover
slips were embedded and analyzed by immunofluores-
cence microscopy.
Cell culture and infection experiments
4T1 cells (mouse mammary gland tumor cell line;
ATCC/Promochem, Germany) were cultured in RPMI
1640 medium. 4T1-HER2 cells (mouse mammary gland
tumor cell line transduced with human HER2, [26]) were
cultured in DMEM medium. SK-BR-3 (human mammary
adenocarcinoma cell line, ATCC Promochem, Germany)
and SK-OV-3 (human ovary adenocarcinoma; ATCC
Promochem, Germany) cells were cultured in McCoy’s
medium. All media (GIBCO) were supplemented with
10% FCS (PAN, Germany) and cultures were kept under
a5 %C O 2 atmosphere at 37°C. If not stated otherwise,
infection of cell lines was performed with 100 bacteria
per cell (MOI 100) as described earlier [14]. Briefly
1.2*10
4 cells were seeded at least 16 h before infection
Table 1 Bacterial strains and plasmids
Strains and plasmids Relevant genotype Reference or source
L. monocytogenes
EGD-e
ΔtrpS × pFlo-trpS
wild-type T. Chakraborty (University of Giessen, Germany [36]
ΔtrpS,inlA/B × pFlo-trpS [32]
Lm-spa
- ΔtrpS,aroA,inlA/B × pFlo-trpS This work
Lm-spa
+ ΔtrpS,aroA,inlA/B,int::Phly-spa × pFlo-trpS This work
ΔtrpS × pSP0-PactA-gfp [36]
Lm-spa
- × pSP0-PactA-gfp ΔtrpS,aroA,inlA/B × pSP0-PactA-gfp This work
Lm-spa
+,aroA
+ × pSP0-PactA-gfp ΔtrpS,inlA/B,int::Phly-spa × pSP0-PactA-gfp This work
Lm-spa
+ × pSP0-PactA-gfp ΔtrpS,aroA,inlA/B,int::Phly-spa × pSP0-PactA-gfp This work
Plasmids
pFlo-trpS Tc
R, [36]
pSP0-PactA-gfp Em
R, gfp-ORF, actA-promoter [36]
pLSV101intAB Em
R, ORI
ts, mutagenesis plasmid [31]
pLSV101intAB::Phly-spa spa-ORF, hly-promoter This work
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tion. The infection was performed in medium lacking
FCS for 1 h and followed by 1 h incubation with medium
containing 10% FCS and 100 μg/ml gentamicin to kill
extracellular bacteria. Cells were then lysed in 0.1%
Triton-X100 and plated in serial dilutions on agar plates
containing the appropriate antibiotics for selection.
Animal handling and in vivo experiments
Six to eight weeks old, female Balb/c SCID mice were
purchased from Harlan, Germany. Xenograft tumor
growth was induced by injecting 5 × 10
4 4T1-HER2
cells into each flank of shaven abdominal skin. When
tumors reached 6 mm in diameter, animals were rando-
mized and divided into three equal groups. 1 × 10
8 bac-
teria were injected into the lateral tail vein and 24 h
post infection mice were sacrificed. Liver, spleen and
tumors were excised and the organ weight was deter-
mined. Liver and spleen were homogenized in 1 ml PBS
and serial dilutions were plated for CFU determination.
Tumors were digested for 30-45 min at 37°C and 5%
CO2 under 100 u/ml DNAse (Sigma, Germany) and 2
μg/ml Dispase (Gibco Invitrogen, Germany) treatment
and homogenized with 70 μma n d4 0μm cell strainers.
Cell counts were determined in a Fuchs-Rosenthal
counting chamber. One part of the cells was treated for
1 h at 37°C with 100 μg/ml gentamicin to kill extracellu-
lar bacteria, while the other part was left untreated.
Cells were washed twice in PBS and finally lysed in 0.1%
Triton-X100 for CFU determination by plating serial
dilutions. The CFU in the tumors was normalized to the
number of cells in the homogenized tumor tissue. The
CFU of liver and spleen was normalized to the organ
weight.
Experimental design and statistical analysis
All experiments were conducted at least three times
with duplicate samples; a representative experiment is
shown. In invasion experiments the CFU was arbitrarily
set on the detection limit if no colonies were visible on
the agar plates. Statistical evaluation was performed on
logarithmized data by two-sided students T-test; p-
values larger than 0.05 were labeled with ‘ns’,p - v a l u e s
of p < 0.05 were marked with ‘*’, p-values of p < 0.005
were marked with ‘**’ and p-values of p < 0.001 were
marked with ‘***’. Differences marked with asteriks were
considered as significant.
Additional material
Additional file 1: Internalization of Cetuximab- or Trastuzumab-
coated Lm-spa
- relative to uncoated Lm-spa
- (-mAb) into different
cell lines.( a) Mouse mammary cancer cell line 4T1, the HER2 transduced
isogenic 4T1-HER2 and (b) the human mammary/ovary cancer cell lines
SK-BR-3 and SK-OV-3, respectively, were infected with a MOI of 100 with
Lm-spa
- after coating with different antibodies. Intracellular colony
forming units (CFU) were determined after gentamicin treatment by
serial plating and the internalization rate of the antibody-coated relative
to the uncoated bacteria was calculated. As expected, the Lm-spa
- strain
(which is InlAB-negative) was not internalized by 4T1, 4T1-HER2, SKBR3 or
SKOV3 cells regardless whether these bacteria were incubated with
Cetuximab or Trastuzumab. Raw CFU data of intracellular bacteria used
for calculation of (a) and (b) is shown in (c) and (d). Raw CFU data of
intracellular bacteria used for calculation of Figure 2a and Figure 2b is
shown in (e) and (f).
Additional file 2: Immunofluorescence microscopy showing the
replication of Lm-spa
+ in the cytosol of SK-BR-3 cells. SK-BR-3 cells
were infected at a MOI 10 with L. monocytogenes strains ΔtrpS × pSP0-
PactA-gfp (a), Lm-spa
- × pSP0-PactA-gfp (b) and Lm-spa
+ × pSP0-PactA-gfp
(c) preincubated with 1 × PBS (i-iii) or Trastuzumab (iv-vi) and GFP-
expression was monitored by fluorescence microscopy at the indicated
time points. Bright field and fluorescence overlay images are shown. The
L. monocytogenes control strain ΔtrpS × pSP0-PactA-gfp shows the typical
intracellular life cycle independent of preincubation with Trastuzumab
(a). L. monocytogenes strain Lm-spa
- × pSP0-PactA-gfp is unable to infect
SK-BR-3 cells as expected (b). L. monocytogenes strain Lm-spa
+ × pSP0-
PactA-gfp infects cells and replicates in the cytosol only after
preincubation with Trastuzumab (c). Because of the aroA deletion Lm-spa
+ × pSP0-PactA-gfp hardly spreads to neighboring cells.
Additional file 3: Examination of antibody binding to Dynabeads
Protein A. Beads were incubated with fluorescently labeled antibodies,
washed intensively to remove excess antibodies, and investigated by
confocal immunofluorescence microscopy. Beads were incubated
simultaneously with the antibodies indicated on the left following bead-
manufacturers protocol. Dynabeads Protein A bind efficiently humanized
Trastuzumab (II), while no direct binding of goat a-human Cy5 antibody
occurs (III). Following pretreatment with the chimeric murine Cetuximab
(IV) or Trastuzumab (not shown), the a-human antibody can be bound
by the beads (IV, V).
Additional file 4: Absence of Dynabeads Protein A internalization
into 4T1-HER2 cells following incubation with goat a-human Cy5
antibody. Following fixation extracellular beads were counterstained by
adding Trastuzumab-Alexa488 into the supernatant. Cells were then
analyzed for bead immunofluorescence using a confocal microscope.
Stacked images of 5 to 16 μm tissue height were analyzed for Cy5-
positive and Alexa488-negative beads. No intracellular beads were
detected, indicating the lack of intrinsic bead uptake by 4T1-HER2 cells.
Additional file 5: Antibody-mediated targeting of uncoated (-mAb)
or Trastuzumab- coated Lm-spa
+ in a xenograft mouse tumor
model. In Balb/c SCID mice 4T1-HER2 cells were injected s.c. to initiate
tumor growth. 14 days later the mice were infected i.v. with 1 × 10
8 CFU
of differently coated Lm-spa
+. After 24 h mice were sacrificed and
tumors, liver and spleen excised aseptically. Organs were homogenized
and plated in serial dilutions. In tumor, liver and spleen no significant
differences in the bacterial counts were detected between the uncoated
and Trastuzumab coated Lm-spa
+.
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